CBP-201

Phase 2Small molecule

CBP-201 is one of 62 small molecule programs targeting Chronic Rhinosinusitis With Nasal Polyps. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Xolair

Roche

Preclinical

25 2

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 3

Asmanex

Novartis

Preclinical

5 4

Celexa

AbbVie

Preclinical

1 5

Spiriva

Boehringer Ingelheim

Preclinical

8 6

CBP-201

SSimcere Pharmaceutical Co., Ltd

Phase 2

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Allergen Immunotherapy Extract

JJohns Hopkins University

Preclinical

1 10

Long-Acting Β2-Agonists (LABA)

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Dermatitis3 trials

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Completed·CConnect Biopharm LLC·Phase 2·NCT04444752·226 enrolled

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Withdrawn·CConnect Biopharm LLC·Phase 3·NCT05614817

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Completed·CConnect Biopharm LLC·Phase 2·NCT05017480·330 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Unknown status·CConnect Biopharm LLC·Phase 2·NCT05905133·360 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Terminated·CConnect Biopharm LLC·Phase 2·NCT04783389·40 enrolled

Asthma1 trial

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Completed·CConnect Biopharm LLC·Phase 2·NCT04773678·322 enrolled

Adult Subject1 trial

A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

Not yet recruiting·SSimcere Pharmaceutical Co., Ltd·Phase 1·NCT06701149·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CBP-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBP-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBP-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Simcere Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSimcere Pharmaceutical Co., Ltd

CBP-201

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Dermatitis3 trials

Safety and Efficacy1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

Asthma1 trial

Adult Subject1 trial

References

Drug Info

Quick Facts

Related News